MICHAEL HALD AUTORISERET FYSIOTERAPIHOLDINGSELSKAB ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  16.0% 11.2% 9.7% 6.3% 5.6%  
Credit score (0-100)  11 20 25 36 41  
Credit rating  BB BB BB BBB BBB  
Credit limit (kDKK)  -0.0 -0.0 -0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  -6.3 -6.3 -4.0 -5.4 -88.3  
EBITDA  -6.3 -6.3 -4.0 -5.4 -88.3  
EBIT  -6.3 -6.3 -4.0 -5.4 -88.3  
Pre-tax profit (PTP)  117.3 413.1 111.9 365.7 3,736.4  
Net earnings  117.3 413.1 111.9 365.7 3,736.4  
Pre-tax profit without non-rec. items  117 413 112 366 3,736  

 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  -593 -180 -67.9 298 3,533  
Interest-bearing liabilities  104 107 105 41.7 4.0  
Balance sheet total (assets)  27.5 99.3 185 354 3,637  

Net Debt  104 107 105 41.7 -698  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -6.3 -6.3 -4.0 -5.4 -88.3  
Gross profit growth  0.0% 0.0% 36.0% -34.4% -1,542.3%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  28 99 185 354 3,637  
Balance sheet change%  -21.4% 261.0% 86.8% 90.6% 928.7%  
Added value  -6.3 -6.3 -4.0 -5.4 -88.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -4.0 -5.0 -5.0 -5.0 -5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  17.7% 92.7% 43.1% 121.4% 187.6%  
ROI %  17.9% 94.0% 44.1% 125.4% 193.1%  
ROE %  375.5% 651.8% 78.6% 151.4% 195.1%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  -95.6% -64.4% -26.8% 84.2% 97.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -1,662.2% -1,706.3% -2,618.0% -776.1% 790.7%  
Gearing %  -17.5% -59.3% -154.2% 14.0% 0.1%  
Net interest  0 0 0 0 0  
Financing costs %  3.4% 3.8% 2.8% 3.7% 26.9%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.2 0.2 0.2 0.6 6.8  
Current Ratio  0.2 0.2 0.2 0.6 6.8  
Cash and cash equivalent  0.0 0.0 0.0 0.0 702.0  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -90.1 -87.9 -89.8 -21.7 603.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0